Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes

NCT04203927 is registered in ClinicalTrials.gov with University of Virginia as lead sponsor.

NCT NCT04203927
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04203927 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Effects of Empagliflozin on Cardiac Microvasculature and Insulin Sensitivity in Subjects With Type 2 Diabetes
Lead sponsor
University of Virginia
Phase
Phase 1
Overall status
Unknown status
Start date
February 1, 2020
Completion date
November 30, 2023
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

insulin sensitivity, type2 diabetes